Spago Nanomedical Reports Promising Results for 177Lu-SN201 in Triple-Negative Breast Cancer Study

Spago Nanomedical AB, a Swedish company in the clinical development phase, announced data from a non-clinical study exploring their leading candidate drug 177Lu-SN201 within the Tumorad radiopharmaceutical program. The study, conducted in a 4T1 orthotopic triple-negative breast cancer model, found that 177Lu-SN201 demonstrated superior anti-tumor effect compared to standard cancer drugs.

The data shows that 177Lu-SN201 reduced tumor growth and significantly increased the survival rate of animals compared to those treated with standard cancer drugs, including immune checkpoint inhibitors, PARP-inhibitors, taxanes, and platinum-based chemotherapy. Additionally, a low and acceptable level of radiotoxicity was observed.

Why this matters: Triple-negative breast cancer is a particularly aggressive form of breast cancer that lacks effective targeted therapies. The promising results of 177Lu-SN201 in this non-clinical study offer hope for a new treatment option that could improve outcomes for patients with this challenging disease.

Mats Hansen, CEO of Spago Nanomedical, described the current results as "very promising" and said they "support further studies of 177Lu-SN201, especially in combination therapy." The company plans to publish the full results from these studies in recognized scientific journals and intends to explore 177Lu-SN201 further in the next step of development.

The study's findings highlight the potential of 177Lu-SN201 as a targeted radiopharmaceutical therapy for triple-negative breast cancer. With its superior anti-tumor effect and acceptable radiotoxicity profile compared to standard treatments, 177Lu-SN201 could represent a significant advancement in the management of this aggressive cancer type. As Spago Nanomedical continues to develop and study this promising candidate drug, the oncology community will closely follow its progress.

Key Takeaways

• Spago Nanomedical's 177Lu-SN201 showed superior anti-tumor effect in triple-negative breast cancer model.
• 177Lu-SN201 significantly increased survival rate compared to standard cancer drugs, including immunotherapies.
• Low and acceptable radiotoxicity levels were observed with 177Lu-SN201 in the non-clinical study.
• Promising results support further development of 177Lu-SN201, especially in combination therapies.
• Findings highlight 177Lu-SN201's potential as a targeted radiopharmaceutical therapy for triple-negative breast cancer.